C. Michael Gibson, MD, FACC

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: BCRI(MODEST), Bayer Corporation(SIGNIFICANT), Janssen Pharmaceuticals, Inc(MODEST), Cardiovascular Research Foundation(MODEST), Johnson & Johnson Corp.(SIGNIFICANT), WebMD(MODEST), The Medicines Company(MODEST), Pharma Mar(SIGNIFICANT), Eli Lilly and Company(SIGNIFICANT), Gilead Sciences, Inc. (SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), Amgen Inc.(SIGNIFICANT), Amarin(SIGNIFICANT), Eli Lilly and Company(MODEST), Novo Nordisk Inc.(MODEST), PharmaMar(MODEST), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Boston Scientific(MODEST), CSL Behring (MODEST), Chiesi(MODEST), Duke Clinical Research Institute(MODEST), Impact Bio LTD(SIGNIFICANT), The Medicine's Company(MODEST), MedImmune, Inc(MODEST), Medtelligence(MODEST), Merck & Co., Inc.(MODEST), Microport(SIGNIFICANT), PERT Consortium(SIGNIFICANT), Sanofi-Aventis(MODEST), Somahlution(SIGNIFICANT), Vereseon Corp(MODEST), Angel Medical(SIGNIFICANT), CSL Behring (SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), Caladrius Biosciences(SIGNIFICANT), Caladrius Biosciences(SIGNIFICANT), CeleCor Therapeutics (SIGNIFICANT), CeleCor Therapeutics (SIGNIFICANT), Eidos Therapeutics (SIGNIFICANT), Eidos Therapeutics (SIGNIFICANT), Kiniksa Pharmaceuticals (SIGNIFICANT), Kiniksa Pharmaceuticals (SIGNIFICANT), Micodrtop, LLC(SIGNIFICANT), Micodrtop, LLC(SIGNIFICANT), Thrombolytic Science (SIGNIFICANT), Thrombolytic Science (SIGNIFICANT), Somahlution (SIGNIFICANT), Vereson Corporation (SIGNIFICANT), CytoSorbents Medical, Inc.(MODEST), AMAG Pharmaceuticals, Inc(MODEST), UpToDate in Cardiovascular Medicine (MODEST) OFFICER, DIRECTOR ETC: Baim Institute (SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Janssen Pharmaceuticals, Inc(SIGNIFICANT), Johnson & Johnson Corp.(SIGNIFICANT), CSL Behring(SIGNIFICANT), Bristol-Myers Squibb Company (NONE), SCAD Alliance(NONE) OTHER FINANCIAL BENEFIT: nference (MODEST)

View Full Disclosure